恩替卡韦和阿德福韦酯治疗慢性乙型肝炎的临床效果比较  

Comparison of Clinical Efficacy of Entecavir and Adefovir Dipivoxil in the Treatment of Chronic Hepatitis B

作　　者：徐圳 Xu Zhen(Department of Human Infection,Guannan County First People's Hospital,Lianyungang 222500,Jiangsu Province,China)

机构地区：[1]灌南县第一人民医院感染科,江苏连云港222500

出　　处：《中国社区医师》2024年第32期38-40,共3页Chinese Community Doctors

摘　　要：目的:探究恩替卡韦与阿德福韦酯在慢性乙型肝炎治疗中的效果差异。方法:选取90例慢性乙型肝炎患者进行研究,均为灌南县第一人民医院(2020年12月—2024年1月)收治,依据随机数字表法分为对照组(45例,采用阿德福韦酯治疗)与观察组(45例,采用恩替卡韦治疗)。对比两组患者炎性标志物水平、乙型肝炎病毒DNA(HBV-DNA)载量、肝功能指标及不良反应发生情况。结果:治疗后,两组白细胞介素-10水平比治疗前高,且观察组比对照组高;两组γ干扰素水平比治疗前低,观察组低于对照组(P<0.05)。治疗8周、16周后,两组患者HBV-DNA载量均较治疗前降低,且观察组比对照组低;治疗16周后,两组HBV-DNA载量比治疗8周后更低,且观察组比对照组低(P<0.05)。治疗后,两组患者碱性磷酸酶、总胆红素及丙氨酸氨基转移酶水平均比治疗前降低,且观察组比对照组低(P<0.05)。此外,观察组不良反应总发生率比对照组低(P=0.024)。结论:相较于阿德福韦酯,恩替卡韦治疗慢性乙型肝炎的临床效果更好,能有效减轻炎症反应,降低HBV-DNA载量,改善患者肝功能,并且具有更高的安全性。Objective:To investigate the difference in the efficacy of entecavir and adefovir disoproxil in the treatment of chronic hepatitis B.Methods:A total of 90 patients with chronic hepatitis B were selected for study,all of whom were admitted to the First People's Hospital of Guannan County(December 2020-January 2024)and divided into control group(45 cases,treated with adefovir disoxif)and observation group(45 cases,treated with entecavir)according to the random number table method.The levels of inflammatory markers,hepatitis B virus DNA(HBV-DNA)load,liver function indexes and adverse reactions were compared between the two groups.Results:After treatment,the level of interleukin-10 in the two groups was higher than that before treatment,and the observation group was higher than that in the control group.The level of interferon in the two groups was lowerγthan before treatment,and the observation group was lower than that in the control group(P<0.05).After 8 weeks and 16 weeks of treatment,the HBV-DNA load in both groups was lower than that before treatment,and the observation group was lower than that in the control group.After 16 weeks of treatment,the HBV-DNA load in the two groups was lower than that after 8 weeks of treatment,and the observation group was lower than that in the control group(P<0.05).After treatment,the levels of alkaline phosphatase,total bilirubin and alanine aminotransferase in the two groups were lower than those before treatment,and the levels in the observation group were lower than those in the control group(P<0.05).In addition,the total incidence of adverse reactions in the observation group was lower than that in the control group(P=0.024).Conclusion:Compared with adefovir disoproxil,entecavir has better clinical effect in the treatment of chronic hepatitis B,can effectively reduce inflammatory response,reduce HBV-DNA load,improve liver function in patients,and has a higher safety profile.

关 键 词：慢性乙型肝炎 恩替卡韦 炎性因子 肝功能 

分 类 号：R512.62[医药卫生—内科学]